What Researchers Did
Researchers reviewed the current understanding of hyperbaric oxygen therapy (HBOT) as a strategy to overcome tumor hypoxia and enhance the effectiveness of various cancer treatments.
What They Found
Preclinical and clinical studies indicate that HBOT enhances drug penetration, augments radiation-induced DNA damage, alleviates hypoxia-driven immunosuppression, and synergizes with immune checkpoint blockade. Mechanistically, HBOT modulates oxidative stress, ferroptosis, angiogenesis, and cancer stem cell maintenance, thereby counteracting hallmarks of therapeutic resistance.
What This Means for Canadian Patients
Integrating HBOT into multimodal oncologic regimens could potentially improve the efficacy of chemotherapy, radiotherapy, and immunotherapy for Canadian patients by overcoming tumor hypoxia. This approach may lead to better treatment responses and outcomes for individuals with difficult-to-treat cancers.
Canadian Relevance
There is no direct Canadian connection mentioned in the study metadata or abstract.
Study Limitations
Controversies persist regarding HBOT's optimal dose-response relationship, long-term safety, and the potential for pro-angiogenic effects under specific conditions.